Publications:

Chemogenomics for drug discovery: clinical molecules from open access chemical probes.

Rsc Chemical Biology

Quinlan, Robert B A RBA; Brennan, Paul E PE

Publication Date: 2021-06-01

Variant appearance in text: SMARCA4: Ala677Gly

PubMed Link: 34458810

Variant Present in the following documents:

• Main text

View BVdb publication page

The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.

Cancer Science

Yuan, Hepei H; Nishikori, Momoko M; Otsuka, Yasuyuki Y; Arima, Hiroshi H; Kitawaki, Toshio T; Takaori-Kondo, Akifumi A

Publication Date: 2021-11

Variant appearance in text: SMARCA4: A677G

PubMed Link: 34449935

Variant Present in the following documents:

• CAS-112-4604.pdf

View BVdb publication page

Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors.

Clinical Epigenetics

Li, Chen C; Wang, Yan Y; Gong, Yueqing Y; Zhang, Tengrui T; Huang, Jiaqi J; Tan, Zhen Z; Xue, Lixiang L

Publication Date: 2021-03-24

Variant appearance in text: BRG1: A677G

PubMed Link: 33761979

Variant Present in the following documents:

• Main text
• 13148_2021_Article_1045.pdf

View BVdb publication page

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies.

Biomarker Research

Tremblay-LeMay, Rosemarie R; Rastgoo, Nasrin N; Pourabdollah, Maryam M; Chang, Hong H

Publication Date: 2018

Variant appearance in text: SMARCA4: A677G

PubMed Link: 30555699

Variant Present in the following documents:

• Main text
• 40364_2018_Article_148.pdf

View BVdb publication page